Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Net Income towards Common Stockholders (2016 - 2025)

Cytosorbents (CTSO) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders fell 35.81% year-over-year to -$3.2 million, compared with a TTM value of -$16.8 million through Sep 2025, up 13.63%, and an annual FY2024 reading of -$20.7 million, up 29.16% over the prior year.
  • Net Income towards Common Stockholders was -$3.2 million for Q3 2025 at Cytosorbents, up from -$4.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$766128.0 in Q4 2022 and bottomed at -$12.2 million in Q3 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$6.1 million, with a median of -$6.4 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 1273.27% in 2021, then soared 91.77% in 2022.
  • Year by year, Net Income towards Common Stockholders stood at -$9.3 million in 2021, then skyrocketed by 91.77% to -$766128.0 in 2022, then plummeted by 758.12% to -$6.6 million in 2023, then fell by 19.92% to -$7.9 million in 2024, then skyrocketed by 59.79% to -$3.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CTSO at -$3.2 million in Q3 2025, -$4.2 million in Q2 2025, and -$1.5 million in Q1 2025.